Evaluating the evidence for genotype‐informed Bayesian dosing of tacrolimus in children undergoing solid organ transplantation: A systematic literature review

Author:

Khatri Dhrita1ORCID,Felmingham Ben1,Moore Claire12,Lazaraki Smaro3,Stenta Tayla1,Collier Lane1,Elliott David A.12ORCID,Metz David456,Conyers Rachel127

Affiliation:

1. Cancer Therapies, Stem Cell Medicine Murdoch Children's Research Institute Parkville Melbourne VIC Australia

2. Department of Paediatrics The University of Melbourne Parkville Melbourne VIC Australia

3. Health Sciences Library Royal Melbourne Hospital, Melbourne Health Australia

4. Department of Nephrology The Royal Children's Hospital Melbourne VIC Australia

5. Murdoch Children's Research Institute Melbourne VIC Australia

6. Department of Paediatrics Monash University Melbourne VIC Australia

7. Children's Cancer Centre, The Royal Children's Hospital Melbourne VIC Australia

Abstract

Tacrolimus, a calcineurin inhibitor, is a highly effective immunosuppressant used in solid organ transplantation (SOT). However, it is characterized by a narrow therapeutic range and high inter‐patient variability in pharmacokinetics. Standard weight‐based dosing followed by empiric dose titration is suboptimal in controlling drug concentrations, increasing risk of rejection or toxicity, particularly in the initial months post transplantation. This review explores the potential of combined pre‐transplant genotyping and pharmacokinetic (PK) modelling to improve tacrolimus dosing in paediatric SOT recipients. A systematic search of Medline, Embase and Cochrane databases identified studies published between March 2013 and March 2023 that investigated genotype‐ and PK model‐informed tacrolimus dosing in children post‐SOT. The Newcastle‐Ottawa Scale assessed study quality. Seven studies encompassing paediatric kidney, heart, liver and lung transplants reported using genotype and model‐informed dosing. A combination of clinical and genetic factors significantly impacts tacrolimus clearance and thus initial dose recommendation. Body size, transplant organ and co‐medications were consistently important, while either time post‐transplant or haematocrit emerged in some studies. Several models were identified, however, with limitations evident in some and with absence of evidence for their effectiveness in optimizing initial and subsequent dosing. This review highlights the development of PK models in paediatric SOT that integrate genotype and clinical covariates to personalize early tacrolimus dosing. While promising, prospective studies are needed to validate and confirm their effectiveness in improving time to therapeutic concentrations and reducing under‐ or overexposure. This approach has the potential to optimize tacrolimus therapy in paediatric SOT, thereby improving outcomes.

Funder

Children's Hospital Foundation

Novo Nordisk Fonden

National Health and Medical Research Council

State Government of Victoria

University of Melbourne

Publisher

Wiley

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3